Influence of Duffy blood type on hydroxyurea (HU) therapy in pediatric sickle cell disease (SCD) patients.

被引：0
|
作者：
Raphael, R [1 ]
OheneFrempong, K [1 ]
Horiuchi, K [1 ]
机构：
[1] UNIV PENN,CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT,PHILADELPHIA,PA 19104
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1972 / 1972
页数：1
相关论文
共 50 条
  • [31] ERYTHROPOIESIS RESPONSE MARKERS TO HYDROXYUREA THERAPY IN PATIENTS WITH SICKLE CELL DISEASE
    Chalvatzi, K.
    Nikolaidou, A.
    Pantelidou, D.
    Chalkia, P.
    Diza, E.
    HAEMATOLOGICA, 2012, 97 : 704 - 705
  • [32] CEFTRIAXONE PHARMACOKINETICS IN PEDIATRIC-PATIENTS WITH SICKLE-CELL DISEASE (SCD)
    EGUIGUREN, JM
    FLYNN, PM
    WANG, WC
    RICHARDSON, D
    CHESNEY, PJ
    WILIMAS, JA
    PEDIATRIC RESEARCH, 1991, 29 (04) : A140 - A140
  • [33] Mortality in sickle cell patients on hydroxyurea therapy
    Bakanay, SM
    Dainer, E
    Clair, B
    Adekile, A
    Daitch, L
    Wells, L
    Holley, L
    Smith, D
    Kutlar, A
    BLOOD, 2005, 105 (02) : 545 - 547
  • [34] Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know
    Rees, Allison L.
    JOURNAL OF PEDIATRIC ONCOLOGY NURSING, 2016, 33 (05) : 339 - 344
  • [35] Lack of hydroxyurea-associated mutagenesis in pediatric sickle cell disease patients
    Torous, Dorothea K. K.
    Avlasevich, Svetlana
    Bemis, Jeffrey C. C.
    Howard, Thad
    Ware, Russell E. E.
    Fung, Chunkit
    Chen, Yuhchyau
    Sahsrabudhe, Deepak
    MacGregor, James T. T.
    Dertinger, Stephen D. D.
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2023, 64 (03) : 167 - 175
  • [36] Hydroxyurea Response in Pediatric Sickle Cell Disease Patients with Alpha Thalasssemia Trait
    Figueiredo, Lisa M.
    Morrone, Kerry A.
    Wei, Catherine
    Cohen, Hillel W.
    Driscoll, Catherine
    Manwani, Deepa
    BLOOD, 2014, 124 (21)
  • [37] Anemia in pediatric sickle cell patients.
    Benkerrou, M
    Brahimi, L
    Vilmer, E
    ANNALES DE PEDIATRIE, 1999, 46 (07): : 479 - 485
  • [38] A phase 1 pharmacokinetics (PK) study of hydroxyurea (HU) 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease (SCD).
    De Montalembert, M
    Bachir, D
    Hulin, A
    Gimeno, L
    Mogenet, A
    Bresson, JL
    Macquin-Mavier, I
    Astier, A
    Galacteros, F
    BLOOD, 2005, 106 (11) : 893A - 893A
  • [39] Sickle cell disease (SCD) patients treated with hydroxyurea have evidence of increased prothrombotic activity.
    Eckman, JR
    Casey, S
    Tomer, A
    BLOOD, 1999, 94 (10) : 417A - 417A
  • [40] Prevalence of Duffy Null and Its Impact on Hydroxyurea Dosing in Children With Sickle Cell Disease
    Menell, Jill S.
    Jackson, S. Raelle
    Kahn, Alissa R.
    Woolbright, William C.
    Schwartz, Leya Y.
    Norko, John
    PEDIATRIC BLOOD & CANCER, 2025,
12345